Hologic's 3D Mammography Technology to be the "New Standard of Care,"
According to Healthcare Research Firm KLAS
98% of Providers Interviewed Say They Would Buy 3D Mammography Again
BEDFORD, Mass., March 19, 2013
BEDFORD, Mass., March 19, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic or the
Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of
premium diagnostics products, medical imaging systems and surgical products
dedicated to serving the healthcare needs of women, announced today the
results of an independent survey by KLAS Research of Hologic 3D mammography
sites in the U.S. The in-depth survey, which was not commissioned by Hologic,
included fifty respondents whose facilities had used Hologic's 3D mammography
(breast tomosynthesis) technology for at least one year. The researcher
reported that "providers are seeing cancers that they would not previously
have seen with traditional digital mammography," and concluded that providers
who are considering 3D mammography "would benefit by quickly jumping on the
This and other findings are available in the recently-issued KLAS report
titled "Breast Tomosynthesis 2013: The Business Case." KLAS specializes in
monitoring and reporting on the performance of healthcare vendors. Working
together with executives from more than 4,500 hospitals and 2,500 clinics,
KLAS helps medical equipment customers and purchasing agents understand which
products are preferred by users.
"This is a really exciting technology to watch evolve," said Monique Rasband,
KLAS Research Director and report author. "In our 2012 report on women's
imaging, we received an overwhelming response from providers to dive deeper
into the clinical and financial impact of tomosynthesis [3D mammography]. And
what we have uncovered in this 2013 study will really help those who are
considering tomosynthesis as a move-forward option. "^ii
Since the clinical benefits of 3D mammography for breast cancer screening are
well-understood and widely-accepted, the report focused on whether the
technology was worth the investment for providers. Nearly 90% of those
surveyed said they are achieving a positive return on investment (ROI).
According to the report, providers saw "a significant reduction in
false-positive callbacks, an increase in new patients, and even workflow
In conventional 2D mammography, the presence of overlapping breast tissue can
make it more difficult to detect cancer and to evaluate areas of suspicion.
Hologic's 3D mammography technology is designed to help overcome these
limitations and allow doctors to see breast tissue more clearly, free from the
interference of overlapping structures. Clinical data shows that the addition
of 3D mammography to a 2D breast cancer screening exam significantly increases
invasive cancer detection while greatly reducing unnecessary callbacks.
"Hologic is pleased that KLAS has validated the reasons why so many providers
are adopting 3D mammography for their patients," said Peter Soltani, Hologic's
Senior Vice President and General Manager of Women's Health. "The ability to
achieve a positive return on investment, while providing a leading-edge
technology with demonstrated clinical advantages is a win-win situation for
everyone. The recently-published Oslo Tomosynthesis Screening Trial showed
that screening with Hologic's 3D mammography finds 40 percent more invasive
cancers than traditional mammography alone. It is encouraging to have
independent data from this report to confirm the positive business impact."
Additional information about 3D mammography, as well as a 3D mammography site
finder, can be found at www.Hologic3D.com.
About Hologic, Inc.:
Hologic, Inc. is a leading developer, manufacturer and supplier of premium
diagnostic products, medical imaging systems, and surgical products. The
Company operates four core business units focused on diagnostics, breast
health, GYN surgical and skeletal health. With a comprehensive suite of
technologies and a robust research and development program, Hologic is
committed to improving lives. The Company is headquartered in Massachusetts.
For more information, visit www.hologic.com.
Hologic and associated logos are trademarks and/or registered trademarks of
Hologic, Inc. and/or its subsidiaries in the United States and/or other
Forward Looking Statement Disclaimer:
This News Release may contain forward-looking information that involves risks
and uncertainties, including statements about the use of Hologic's 3D
mammography systems. There can be no assurance the system will achieve the
benefits described herein and that such benefits will be replicated in any
particular manner with respect to an individual patient as the actual effect
of the use of the systems can only be determined on a case-by-case basis
depending on the particular circumstances and patient in question. Hologic
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to the data or statements presented herein to reflect any
change in the Company's expectations or any change in events, conditions or
circumstances on which any such data or statements are based.
^i "The Bottom Line," KLAS Breast Tomosynthesis 2013: The Business Case,
February 2013. pp. 3. © KLAS Enterprises, LLC. All rights reserved.
www.KLASresearch.com < http://www.KLASresearch.com >
^iii "How Providers are Achieving a Positive ROI," KLAS Breast Tomosynthesis
2013: The Business Case, February 2013. pp. 3. © KLAS Enterprises, LLC. All
rights reserved. www.KLASresearch.com < http://www.KLASresearch.com >
Marianne McMorrow Jim Culley
Global Marketing and Advertising Publicist Sr. Director of
SOURCE Hologic, Inc.
Press spacebar to pause and continue. Press esc to stop.